Summary by Futu AI
On May 13, 2024, Novo Nordisk A/S announced positive results from the FRONTIER 2 trial, a phase 3a study evaluating the efficacy and safety of Mim8, a prophylactic treatment for haemophilia A. The trial, which included 254 participants aged 12 and older, demonstrated that both once-weekly and once-monthly subcutaneous injections of Mim8 significantly reduced treated bleeding episodes compared to no prophylaxis and prior coagulation factor prophylaxis treatments. The study met its co-primary endpoints, with once-weekly and once-monthly Mim8 showing reductions of 97% and 99% in treated bleeds, respectively, in participants without prior prophylaxis. Additionally, a majority of participants experienced zero treated bleeds. The intra-patient analysis also revealed substantial reductions in treated bleeds compared to prior prophylaxis. Mim8 was well-tolerated with no reported deaths or...Show More